About
About START

Welcome to the START Center for Cancer Research. We are a global leader in cancer research, dedicated to the relentless pursuit of hope for patients and their families.

About

Company

Hope Hub

Leadership

Principal Investigators

Careers

Contact

Our Services

Preclinical

Early Phase
Who We Serve
Who We Serve

We believe that every patient should have the opportunity to access clinical trials, regardless of where they receive their cancer treatment.

Visit The START Hope Hub

We believe that every patient should have the opportunity to access clinical trials, regardless of where they receive their cancer treatment. Designed to help you understand, explore, and enroll in early-phase oncology trials, the START Hope Hub will help guide you through the clinical trial process with confidence.

Explore Hope Hub

Patients & Family

Patients

Explore Clinical Trials

About Clinical Trials

Patient Stories

Patient Advocacy Groups

Referring Physicians

Referring Physicians

Hospitals & Oncology Practices

Hospitals & Oncology Practices

Pharma

Pharma
START Locations
START Research Centers

100,000+ square feet of world-class research facilities

United States Locations

START - San Antonio

START - Midwest

START - Mountain Region

START - Carolinas

START - Dallas Fort Worth

START - New York City (Coming Soon)

START - New Jersey (Coming Soon)

START - Los Angeles (Coming Soon)

Europe Locations

START - Madrid - CIOCC

START - Madrid - FJD

START - Barcelona

START - Rioja

START - Pediatrics

START - Lisbon

START - Dublin
Resources
Resources

Stay up to date with everything at START, from blog insights and press and newsroom updates to expert-led webinars and much more.

Resources

Blog

Events

Newsroom

Press

Publications

Webinars

Featured Resources

Newsroom

XenoSTART and Minerva Imaging Expand Partnership to Deliver Integrated PDX-Radiopharmaceutical Drug Development Platform

Newsroom

START and Advarra Unite to Deliver Unmatched Speed, Quality, and Predictability for Early-Phase Oncology Trials
Hope Hub
Find a Trial

Publication

Predictive and therapeutic implications of a novel PLCy1/SHP2-driven mechanism of cetuximab resistance in metastatic colorectal cancer

Predictive and therapeutic implications of a novel PLCy1/SHP2-driven mechanism of cetuximab resistance in metastatic colorectal cancer Read More »

Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumors (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study

Leave a Comment / Publication / Joel E

Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumors (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study Read More »

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial

Leave a Comment / Publication / Joel E

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial Read More »

T cell engagers in solid tumors kick the door down

Leave a Comment / Publication / Joel E

T cell engagers in solid tumors kick the door down Read More »

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors

Leave a Comment / Publication / Joel E

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors Read More »

Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy

Leave a Comment / Publication / Joel E

Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy Read More »

Combination Immunotherapy With IDO Inhibitors: Defining a Future Through Biomarker-Guided Patient Selection

Leave a Comment / Publication / Joel E

Combination Immunotherapy With IDO Inhibitors: Defining a Future Through Biomarker-Guided Patient Selection Read More »

Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody

Leave a Comment / Publication / Joel E

Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody Read More »

T-cell–engaging Therapy for Solid Tumors

Leave a Comment / Publication / Joel E

T-cell–engaging Therapy for Solid Tumors Read More »

HERVs establish a distinct molecular subtype in stage II/III colorectal cancer with poor outcome

Leave a Comment / Publication / Joel E

HERVs establish a distinct molecular subtype in stage II/III colorectal cancer with poor outcome Read More »

Partnership

Quis volutpat scelerisque quis massa in dolor nunc lectus cursus.

Varius nec, elit turpis amet, proin ut sed nec donec auctor dolor arcu, sollicitudin.

Enim nulla elementum sodales dapibus orci, sed quam mattis aliquam dui penatibus aliquet feugiat nisl laoreet placerat pellentesque duis semper pellentesque tempor placerat nam parturient magna volutpat auctor mattis imperdiet sapien ut tortor id amet tempor tortor, augue facilisi mi.

About START

About

Our Services

Who We Serve

Visit The START Hope Hub

Patients & Family

Referring Physicians

Hospitals & Oncology Practices

Pharma

Resources

Resources

Featured Resources

XenoSTART and Minerva Imaging Expand Partnership to Deliver Integrated PDX-Radiopharmaceutical Drug Development Platform

START and Advarra Unite to Deliver Unmatched Speed, Quality, and Predictability for Early-Phase Oncology Trials

Publication

Partnership

Quis volutpat scelerisque quis massa in dolor nunc lectus cursus.